Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review

Am J Kidney Dis. 2018 Nov;72(5):756-757. doi: 10.1053/j.ajkd.2018.07.008.

Authors

David J Tunnicliffe¹, Suetonia C Palmer²

Affiliations

¹ Sydney School of Public Health, University of Sydney, NSW, Australia; Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia. Electronic address: david.tunnicliffe@health.nsw.gov.au.
² Department of Medicine, University of Otago, Christchurch, New Zealand.

PMID: 30343732
DOI: 10.1053/j.ajkd.2018.07.008

No abstract available

Publication types

Comparative Study
Review

MeSH terms

Biological Products / therapeutic use*
Cyclophosphamide / administration & dosage
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Immunosuppressive Agents / therapeutic use*
Infusions, Intravenous
Lupus Nephritis / diagnosis
Lupus Nephritis / drug therapy*
Lupus Nephritis / mortality
Male
Mycophenolic Acid / therapeutic use*
Prognosis
Remission Induction
Risk Assessment
Severity of Illness Index
Survival Analysis
Treatment Outcome

Substances

Biological Products
Immunosuppressive Agents
Cyclophosphamide
Mycophenolic Acid